News | November 05, 2024
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Subscribe To Our Newsletter & Stay Updated
